Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report

Frontiers in Oncology

Xiaofei Zhao¹  Daobing Zeng¹  Guangming Li¹  Liang Di¹  Yanfang Song³  Yanrui Zhang³  Huanhuan Liu³  Luyan Lou³ 

[1] Clinical Center for Liver Cancer, Capital Medical University, Beijing, China;General Surgery Department, Beijing Youan Hospital, Capital Medical University, Beijing, China;Medical Affairs Department, Acornmed Biotechnology Co. Ltd., Beijing, China;

关键词: cholangiocarcinoma;    ERBB2 mutation;    treatment;    trastuzumab;    case report;   

DOI  :  10.3389/fonc.2022.918297

来源: DOAJ

【 摘 要 】

The identification of ERBB2 (HER2) alteration in some solid tumors has become critically important due to the actionable events predictive of response to anti-HER2 therapy. However, the efficacy of ERBB2 mutated hilar cholangiocarcinoma (hCCA) against ERBB2 is rarely reported. Here we report a 76-year-old female diagnosed with hCCA complicated by liver metastases after radical resection. The next-generation sequencing assay showed that the tumor had an ERBB2 mutation. Then, the patient was treated with trastuzumab plus capecitabine. After 2 months of treatment, she had a partial response. Until now, the patient is still alive. This study has shown the potential of trastuzumab combined with capecitabine as an effective treatment for hilar cholangiocarcinoma complicated by liver metastases harboring ERBB2 alterations.

【 授权许可】

Unknown